The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker results from the KGOG3056/NIRVANA-R trial: Maintenance niraparib plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.
 
Hyun-Woong Cho
Consulting or Advisory Role - Merck KGaA; onconic therapeutics
Speakers' Bureau - MSD Oncology; Roche; Takeda
Research Funding - Advenchen Laboratories; Boryung Pharmaceuticals; Chong Kun Dang Pharmaceutical; Corcept Therapeutics; Hanmi; Merck KGaA; OncoQuest; Regeneron
 
Jung-Yun Lee
Honoraria - AstraZeneca; Genmab; Merck Serono; MSD; Regeneron; Seagen
Consulting or Advisory Role - Abbvie (Inst); Advenchen Laboratories (Inst); Alkermes (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); bms (Inst); CanariaBio (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); genemedicine (Inst); Genmab (Inst); GI Innovation (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Janssen Oncology (Inst); Kelun (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD; Novartis (Inst); onconic therapeutics (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Sutro Biopharma (Inst); Synthon (Inst); Takeda (Inst); Torl Biotherapeutics (Inst); Zymeworks (Inst)
Speakers' Bureau - AstraZeneca; Eisai; MSD; Roche; Takeda
Research Funding - Ascendis Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); Mersana (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); OncoQuest Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst); Takeda (Inst)
 
Jeong-Yeol Park
No Relationships to Disclose
 
Myong Cheol Lim
No Relationships to Disclose
 
Byoung-Gie Kim
No Relationships to Disclose
 
Min Chul Choi
No Relationships to Disclose
 
Se Ik Kim
No Relationships to Disclose
 
Dae Hoon Jeong
No Relationships to Disclose